[1]CurrentPatentAssignee:EASTCHINAPHARMACEUTICALGROUPLIMITEDCOLTD-CN107365275,2017,ALocationinpatent:Paragraph0061;0062;0063;0064;0065;0066-0070
[2]CurrentPatentAssignee:SHANGHAISHIJIBIOLOGICALTECH;SEASONSBIOTECHNOLOGYTAIZHOU;SHANGHAISEASONSBIOTECHNOLOGY-US2018/29998,2018,A1Locationinpatent:Paragraph0076-079
[3]CurrentPatentAssignee:LUPINLIMITED-WO2017/60827,2017,A1Locationinpatent:Page/Pagecolumn12;13
[4]Asaki,Tetsuo;Hamamoto,Taisuke;Sugiyama,Yukiteru;Kuwano,Keiichi;Kuwabara,Kenji[BioorganicandMedicinalChemistry,2007,vol.15,#21,p.6692-6704]
[5]Asaki,Tetsuo;Kuwano,Keiichi;Morrison,Keith;Gatfield,John;Hamamoto,Taisuke;Clozel,Martine[JournalofMedicinalChemistry,2015,vol.58,#18,p.7128-7137]
[6]CurrentPatentAssignee:JIANGSUFANGSHENGPHARMACEUTICAL-CN113480484,2021,ALocationinpatent:Paragraph0027;0029;0030;0032;0033;0035
[7]CurrentPatentAssignee:NANJINGNMGADDS-CN106957269,2017,ALocationinpatent:Paragraph0025;0026
[8]CurrentPatentAssignee:NIPPONSHINYAKUCOLTD-EP1400518,2004,A1Locationinpatent:Page53-54
[9]CurrentPatentAssignee:MEGAFINEPHARMA(P)LTD.-WO2017/42828,2017,A2Locationinpatent:Page/Pagecolumn45-46
[10]CurrentPatentAssignee:HONOURRD-WO2017/168401,2017,A1Locationinpatent:Page/Pagecolumn11
[11]CurrentPatentAssignee:VIATRISINC-WO2018/15974,2018,A1Locationinpatent:Page/Pagecolumn39;40
[12]CurrentPatentAssignee:NANJINGUNIVERSITYOFSCIENCEANDTECHNOLOGY-CN112939877,2021,ALocationinpatent:Paragraph0059-0063;0064-0066;0069-0070
[1]Asaki,Tetsuo;Kuwano,Keiichi;Morrison,Keith;Gatfield,John;Hamamoto,Taisuke;Clozel,Martine[JournalofMedicinalChemistry,2015,vol.58,#18,p.7128-7137]
[2]CurrentPatentAssignee:MEGAFINEPHARMA(P)LTD.-WO2017/42828,2017,A2
[3]CurrentPatentAssignee:MEGAFINEPHARMA(P)LTD.-WO2017/42828,2017,A2
[4]CurrentPatentAssignee:LUPINLIMITED-WO2017/60827,2017,A1
[5]CurrentPatentAssignee:HONOURRD-WO2017/168401,2017,A1
[6]CurrentPatentAssignee:NANJINGNMGADDS-CN106957269,2017,A
[7]CurrentPatentAssignee:VIATRISINC-WO2018/15974,2018,A1
[8]CurrentPatentAssignee:EASTCHINAPHARMACEUTICALGROUPLIMITEDCOLTD-CN107365275,2017,A
[9]CurrentPatentAssignee:SHANGHAISEASONSBIOTECHNOLOGY;SEASONSBIOTECHNOLOGYTAIZHOU;SHANGHAISHIJIBIOLOGICALTECH-US2018/29998,2018,A1
[10]CurrentPatentAssignee:JIANGSUFANGSHENGPHARMACEUTICAL-CN113480484,2021,A
[11]Zhang,Kun;Hu,Kaizhao;Li,Qian;Li,Min;Gao,Ke;Yang,Kecheng;Zhao,Bing;Shi,Xiao-Jing;Zhang,Lirong;Liu,Hong-Min[JournalofMedicinalChemistry,2023,vol.66,#11,p.7221-7242]
[1]Asaki,Tetsuo;Kuwano,Keiichi;Morrison,Keith;Gatfield,John;Hamamoto,Taisuke;Clozel,Martine[JournalofMedicinalChemistry,2015,vol.58,#18,p.7128-7137]
[2]CurrentPatentAssignee:MEGAFINEPHARMA(P)LTD.-WO2017/42828,2017,A2
[3]CurrentPatentAssignee:MEGAFINEPHARMA(P)LTD.-WO2017/42828,2017,A2
[4]CurrentPatentAssignee:HONOURRD-WO2017/168401,2017,A1
[5]CurrentPatentAssignee:VIATRISINC-WO2018/15974,2018,A1
[6]CurrentPatentAssignee:SHANGHAISEASONSBIOTECHNOLOGY;SEASONSBIOTECHNOLOGYTAIZHOU;SHANGHAISHIJIBIOLOGICALTECH-US2018/29998,2018,A1
[7]Zhang,Kun;Hu,Kaizhao;Li,Qian;Li,Min;Gao,Ke;Yang,Kecheng;Zhao,Bing;Shi,Xiao-Jing;Zhang,Lirong;Liu,Hong-Min[JournalofMedicinalChemistry,2023,vol.66,#11,p.7221-7242]
[1]CurrentPatentAssignee:HEBEIUNIVERSITYOFSCIENCESANDTECHNOLOGY-CN106008364,2016,ALocationinpatent:Paragraph0023
[2]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2017/40872,2017,A1Locationinpatent:Paragraph0097-0098
[3]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2018/22704,2018,A1Locationinpatent:Paragraph00142-00144
[1]CurrentPatentAssignee:LUPINLIMITED-WO2017/42731,2017,A1Locationinpatent:Page/Pagecolumn11;12
Title: Selexipag for the treatment of pulmonary arterial hypertension.
Journal: Expert review of respiratory medicine 20160101
Title: Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions 20150101
Title: Pathways in pulmonary arterial hypertension: the future is here.
Journal: European respiratory review : an official journal of the European Respiratory Society 20121201
Title: Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
Journal: The Journal of pharmacology and experimental therapeutics 20101001
Title: A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.
Journal: The Journal of pharmacology and experimental therapeutics 20080901
Title: Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist.
Journal: Bioorganic & medicinal chemistry 20071215
Title: Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists.
Journal: Bioorganic & medicinal chemistry 20071101
Title: 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
Journal: The Journal of pharmacology and experimental therapeutics 20070901
Title: Prostanoid receptors and their biological actions.
Journal: Progress in lipid research 19930101
Title: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.
Journal: Nature 19761021
Title: Kuwano K, et al. 2--[(5,6-diphenylpyrazin-2-yl)(isopropyl)aminobutoxy-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007 Sep;322(3):1181-8.
Title: Mous DS, et al. Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature. Am J Physiol Lung Cell Mol Physiol. 2018 May 10.
